Skip to main content

Sunshine Biopharma Inc.

corporate_fare Company Profile

Sunshine Biopharma Inc.

SBFM·NASDAQ·Life Sciences·CIK 0001402328

Sunshine Biopharma is a pharmaceutical company that researches and offers medicines in therapeutic areas such as oncology and antivirals. The company operates through two wholly-owned Canadian subsidiaries. Nora Pharma Inc. currently markets 71 generic prescription drugs in Canada. Sunshine Biopharma Canada Inc. develops and sells over-the-counter (OTC) supplements. Sunshine Biopharma is also advancing a proprietary drug development program. This includes K1.1 mRNA, an LNP encapsulated mRNA designed to target liver cancer, and SBFM-PL4, a protease inhibitor intended for the treatment of SARS Coronavirus infections. The company's commercial operations focus on acquiring rights to pharmaceutical products for sale, primarily in Canada and with a goal for global expansion. These rights are secured through strategic arrangements. Under In-licensing and Supply Agreements, Nora Pharma acquires rights to import, market, sell, and distribute products in Canada by purchasing drug dossiers from strategic partners. Nora Pharma then files these dossiers with Health Canada for regulatory approval, a process that takes an average of 12 months, and sells the products under the Nora Pharma label. Through Cross-licensing, Nora Pharma obtains rights to import, market, sell, and distribute products in Canada via authorization letters from pharmaceutical partners whose products are already approved in Canada. Nora Pharma still requires its own Health Canada approval, which averages 45-60 days, and sells these products under its own label. Lastly, Distribution Agreements allow Nora Pharma to market, sell, and distribute products in Canada by signing agreements with pharmaceutical partners whose products are already Health Canada approved, with these products sold under the partners' label. Generic drugs are pharmaceutically equivalent to brand-name drugs, containing identical medicinal ingredients in the same amounts.

Sunshine Biopharma Inc. (NASDAQ:SBFM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for SBFM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for SBFM spans S-1, 10-Q, DEF 14A, PRE 14C.

Recent high-impact activity:

  • Sunshine Registers 31.1M Series B Warrant Shares at $2.7674 Strike
  • Sunshine Biopharma Q3 Loss Widens to $5.20/Share, Missing Estimates
  • Sunshine Biopharma Q3 Loss Widens to $1.2M; $14.6M Cash Funds 29 Months
  • Sunshine Biopharma Seeks 7,000,000-Share Equity Plan Increase at Dec 29 Meeting
  • Sunshine Biopharma Sets Reverse Split to Hold Nasdaq Listing

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$36.31M
Net Income
-$5.98M
Op. Cash Flow
-$5.33M
Free Cash Flow
-$5.51M
Gross Profit
$12.26M
Operating Income
-$6.23M
Cash & Equivalents
$9.12M
Debt / Equity
0.00×
Net Margin
-16.5%
Shares Outstanding
4.91M sh
Source: 10-K · filed 2026-04-03 · accession 0001683168-26-002644

Short Interest & Short Volume

1.03 days to cover

FINRA reported short interest of 176,303 shares in SBFM as of the October 30, 2026 settlement, a 79.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 41.3% of SBFM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)176,303 shares as of October 30, 2026
Change vs prior period▼ 79.0%
Days to cover1.03 at avg daily volume of 170,382
Daily short volume (FINRA facilities)41.3% of 10,756 shares on November 20, 2026
5-day average short volume37.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for SBFM, detected from its recent SEC filings · based on capital-structure filings through 2026-10-14.

3 recent capital raisesATM program3 shelf registrationsreverse split

CEO Approves Warrant Stockholder Provisions · Share Combination Event Price Floor

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$2.23 +0.22% today
52-week range · as of 2026-11-18 $2.23 – $464
Market cap
$1.84M
Volume
23.3K (0.2× avg)
3-mo avg 102.5K
Live data · 2026-11-21 13:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SBFM - Latest Insights

SBFM
Nov 18, 2026, 4:05 PM EST
Filing Type: S-1
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $2.23 info
Change: -$0.1751 (-7%) info
Market Cap: $1.837M info
SBFM
Nov 12, 2026, 11:56 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $2.23 info
Change: -$0.4651 (-17%) info
Market Cap: $1.837M info
SBFM
Nov 12, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.23 info
Change: -$0.5751 (-20%) info
Market Cap: $1.837M info
SBFM
Nov 12, 2026, 4:05 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.23 info
Change: -$0.5651 (-20%) info
Market Cap: $1.837M info
SBFM
Oct 22, 2026, 9:25 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.1638
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Oct 14, 2026, 5:21 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.232
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Oct 09, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
8
Updated Oct 14, 4:07 PM ET — CEO Steve Slilaty, holding ~90% voting power, approved by written consent the issuance of over 20% of outstanding shares at a discount and…
Price at Filing: $0.3269
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Oct 09, 2026, 5:24 PM EDT
Filing Type: 424B4
Importance Score:
8
Price at Filing: $0.3205
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Oct 09, 2026, 11:17 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.373
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Oct 08, 2026, 8:17 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.4892
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Oct 02, 2026, 4:49 PM EDT
Filing Type: S-1
Importance Score:
8
Updated Oct 2, 5:16 PM ET — The offering is priced at $0.6876 per unit, a modest discount to the current $0.6495 market price, with each unit including a Series D Warr…
Price at Filing: $0.6665
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Sep 16, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.01
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Sep 16, 2026, 8:31 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Aug 28, 2026, 4:15 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $1.11
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Aug 19, 2026, 9:04 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Aug 13, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Aug 03, 2026, 8:52 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Jul 20, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Jul 20, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.73
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
SBFM
Jul 10, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.13
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets